Maria Mendez-Perez

This inventor holds 14 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Sanofi, Genzyme Corporation, Sanofi-Aventis. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maria Mendez-Perez. Retrieved from https://idiyas.com/inventor/maria-mendez-perez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 4)

% Patents Active = 71.4

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 8.8

ph-index = 3

Forward Citations = 19(Granted Patents)

Location History:

Frankfort am Main, DE (2014)
Frankfurt-am-Main, DE (2012 - 2024)

Company Filing History:

Years Active: 2012-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655139 - Isoxazolidines as RIPK1 inhibitors and use thereof (2026-06-16),

2. 11897876 - Isoxazolidines as RIPK1 inhibitors and use thereof (2024-02-13),

3. 10980816 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2021-04-20),

4. 10736904 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2020-08-11),

5. 10500212 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2019-12-10),

6. 10220044 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2019-03-05),

7. 9776991 - Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase (2017-10-03),

8. 9744176 - Therapeutic uses of novel thienopyrimidine derivatives (2017-08-29),

9. 9540391 - Isomannide derivatives as inhibitors of soluble epoxide hydrolase (2017-01-10),

10. 9115140 - Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof (2015-08-25),

11. 8846712 - 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors (2014-09-30),

12. 8686150 - 6-(4-hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors (2014-04-01),

13. 8309721 - HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof (2012-11-13),

14. 8163750 - Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 (2012-04-24),

Title: Maria Mendez-Perez: Innovator in Pharmaceutical Chemistry

Introduction

Maria Mendez-Perez is a prominent inventor based in Frankfurt am Main, Germany. She has made significant contributions to the field of pharmaceutical chemistry, holding a total of 13 patents. Her work focuses on developing innovative compounds that have therapeutic applications.

Latest Patents

Among her latest patents is the invention titled "Isoxazolidines as RIPK1 inhibitors and use thereof." This patent relates to isoxazolidines and their application as receptor-interacting protein kinase 1 inhibitors, particularly in the treatment of diseases and disorders mediated by RIP kinase 1. Another notable patent is for "Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof." This invention involves compounds of a specific formula, detailing their preparation processes and therapeutic applications.

Career Highlights

Maria has worked with notable companies in the pharmaceutical industry, including Sanofi and Sanofi-Aventis. Her experience in these organizations has allowed her to contribute to the development of groundbreaking therapies.

Collaborations

Throughout her career, Maria has collaborated with esteemed colleagues such as Olivier Duclos and Jean-Christophe Carry. These partnerships have further enhanced her research and innovation efforts.

Conclusion

Maria Mendez-Perez is a distinguished inventor whose work in pharmaceutical chemistry continues to impact the field significantly. Her innovative patents and collaborations reflect her dedication to advancing medical science.

Profile summary based on public USPTO records.